Sangamo Therapeutics Inc

NASDAQ:SGMO  
11.47
-0.30 (-2.55%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.65B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$24.2 Million
Adjusted EPS-$0.30
See more estimates
10-Day MAN/A
50-Day MAN/A
200-Day MAN/A
See more pivots

Sangamo Therapeutics, Inc. Stock, NASDAQ:SGMO

7000 Marina Boulevard, 501 Canal Boulevard, Brisbane, California 94005
United States of America
Phone: +1.510.970.6000
Number of Employees: 354

Description

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.